Beta Drugs (BETA) had a P/E of 26.6× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 36% below their 52-week high. It earns ROCE of 18% and ROE of 19%, and sales and net profit grew 19% and 11% a year over 3 years. Debt is 0.60× equity. It is a small-cap company with a market cap of ₹1,831 Cr, ranked 62nd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 5.6% over the past year.
- ₹1,849.90
- ₹1,849.90
- ₹1,770.60
- ₹1,840.70
- 15.9K
Health check
- ReturnsBehind
+5.6% over a year, better than 1 of 7 peers.
- Price tagIn line
P/E 26.6 vs industry 28.7.
- GrowthSteady
Sales +19.2%, profit +10.5% a year over 3 years.
- ProfitabilityAverage
ROCE 17.9% vs peer median 17.9%.
- Balance sheetFair
Debt 0.60× equity, interest covered 4.6×, Piotroski 4 of 9.
- Red flags2 to check
36% below its 52-week high.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹1,831 Cr
- Small cap
- P/E
- 26.6
- Industry 28.7
- Price to book
- 7.48
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- 18.8%
- Peers 14.7%
- ROCE
- 17.9%
- Peers 17.9%
- Debt to equity
- 0.60
- Debt ₹148 Cr
- EPS (TTM)
- ₹67.90
- Face value ₹10
- OPM (TTM)
- 20.3%
- Net margin 11.1%
- Sales growth
- +25.3%
- Latest quarter vs a year ago
- Profit growth
- +35.1%
- Latest quarter vs a year ago
- Price to sales
- 4.46
- EV/EBITDA 23.2
Strengths and risks
Strengths
- Return on equity of 18.8%.
- Quarterly profit up 35.1% on a year ago.
- Quarterly sales up 25.3% on a year ago.
- Positive operating cash flow in each of the last 4 years.
Risks to check
- 36% below its 52-week high.
- Promoter stake down from 64.9% to 58.9%.
About Beta Drugs
Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India.
- Headquarters
- Panchkula
- Employees
- 455
- Sector
- Healthcare
- ISIN
- INE351Y01019
- Website
- betadrugslimited.com
Price range
- Avg volume (3M)
- 44.8K
- 1-year return
- plus 5.6%
- From 52-week high
- minus 35.7%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| BETABeta Drugs | 1,805.90 | minus 1.89% | 1,831 | 26.6 | 7.48 | 17.9% | 18.8% | 20.3% | 19.2% | 10.5% | 0.00% | plus 5.6% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 100 | 103 | 87.3 | 94 | 126 | |
| 80.5 | 82.1 | 70.3 | 76.3 | 98.2 | |
| 19.7 | 21.3 | 17 | 17.7 | 27.4 | |
| 19.7% | 20.6% | 19.5% | 18.8% | 21.8% | |
| 3 | 3 | 2.3 | 2.9 | 1.6 | |
| 3.3 | 3.6 | 4.4 | 3.9 | 2.6 | |
| 3.7 | 4.2 | 4.4 | 4.8 | 4.3 | |
| 15.6 | 16.4 | 10.5 | 11.8 | 22 | |
| 25.2% | 25.7% | 18.7% | 23.5% | 25.2% | |
| 11.7 | 12.2 | 8.5 | 9 | 15.8 | |
| 11.59 | – | 8.40 | 8.93 | 14.78 |
Profit & loss
- Sales CAGR 3Y
- +19.2%
- Profit CAGR 3Y
- +10.5%
- EPS CAGR 3Y
- +10.4%
- ROE
- 18.8%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 227 | 296 | 362 | 385 | |
| – | +30.2% | +22.5% | +6.2% | |
| 174 | 236 | 288 | 309 | |
| 53.4 | 59.9 | 74.6 | 75.7 | |
| 23.5% | 20.3% | 20.6% | 19.7% | |
| 0.3 | 1.3 | 6.2 | 10.9 | |
| 2.3 | 2.7 | 6.7 | 15 | |
| 10.4 | 9.8 | 12.5 | 17.2 | |
| −0 | −0 | −4.6 | – | |
| 41.1 | 48.8 | 57 | 54.4 | |
| 25.2% | 25.3% | 25.5% | 23.7% | |
| 30.7 | 36.4 | 42.4 | 41.5 | |
| – | +18.6% | +16.4% | minus 2.2% | |
| 30.43 | 37.90 | 42.02 | 40.92 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 9.6 | 9.6 | 10.1 | 10.1 | |
| 113 | 148 | 187 | 235 | |
| 20.3 | 14.7 | 138 | 148 | |
| 55.2 | 82.3 | 101 | 103 | |
| 198 | 254 | 436 | 496 | |
| 62.1 | 67 | 91.3 | 126 | |
| 4 | 7.8 | 10.9 | 10.5 | |
| 19.2 | 28.6 | 147 | 125 | |
| 113 | 151 | 187 | 234 | |
| 198 | 254 | 436 | 496 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 23.4 | 30.9 | 36.1 | 37.3 | |
| −19.1 | −14 | −35.7 | −51.4 | |
| −2.5 | −7.5 | 118 | −8.1 | |
| 1.8 | 9.5 | 118 | −22.2 | |
| −18.2 | −11.6 | −36.9 | −53.5 | |
| 5.2 | 19.3 | −0.7 | −16.2 |
Shareholding pattern
- Promoters58.91%
- Public41.09%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 58.91% | 41.09% | minus 0.19 | |
| 30 Jun 2026 | 59.10% | 40.90% | 0.00 | |
| 25 May 2026 | 59.10% | 40.90% | minus 5.53 | |
| 31 Mar 2026 | 64.63% | 35.37% | minus 0.27 | |
| 31 Dec 2025 | 64.90% | 35.10% | – |
Major shareholders
Filings & events
News
No recent news coverage found.